|
PREPL expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62503344114384E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.06168415672892E-13 |
| Normal-vs-Stage2 |
2.09820000000027E-05 |
| Normal-vs-Stage3 |
2.90878432451791E-14 |
| Normal-vs-Stage4 |
3.76499942333908E-11 |
| Stage1-vs-Stage2 |
2.686800E-01 |
| Stage1-vs-Stage3 |
4.176300E-02 |
| Stage1-vs-Stage4 |
9.407600E-02 |
| Stage2-vs-Stage3 |
1.986190E-02 |
| Stage2-vs-Stage4 |
3.317900E-02 |
| Stage3-vs-Stage4 |
9.075000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.33066907387547E-16 |
| Normal-vs-AfricanAmerican |
1.838820E-04 |
| Normal-vs-Asian |
4.11120000265441E-08 |
| Caucasian-vs-AfricanAmerican |
1.987790E-01 |
| Caucasian-vs-Asian |
4.242000E-01 |
| AfricanAmerican-vs-Asian |
5.641200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.47881706880071E-13 |
| Normal-vs-Female |
1.64557256709941E-12 |
| Male-vs-Female |
1.702950E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.47581988033608E-12 |
| Normal-vs-Age(41-60Yrs) |
7.7715611723761E-13 |
| Normal-vs-Age(61-80Yrs) |
9.01934082975231E-12 |
| Normal-vs-Age(81-100Yrs) |
1.021050E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.049000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.032000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.019000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.298600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.945000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.787000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.618500E-04 |
| Classical-VS-Follicular |
1.193230E-01 |
| Classical-VS-Other |
2.841400E-01 |
| Classical-VS-Normal |
7.63380025858851E-10 |
| Tall-VS-Follicular |
6.33380000000239E-05 |
| Tall-VS-Other |
6.767000E-01 |
| Tall-VS-Normal |
2.57127652503186E-13 |
| Follicular-VS-Other |
1.720830E-01 |
| Follicular-VS-Normal |
1.73489999999443E-06 |
| Other-VS-Normal |
6.388400E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.70814490224802E-12 |
| Normal-vs-N1 |
2.94841928649703E-12 |
| N0-vs-N1 |
4.326300E-02 |
|
|
